














Clinical Guidelines from the 2025 International Symposium on Breast Diseases of Inland São Paulo: Imaging Assessment and Management of B3 Breast Lesions

Eduardo Carvalho Pessoa^{1,2*} , Fabio Bagnoli^{2,3,4} , Marcelo Madeira⁵ , Joaquim Teodoro Araujo Neto^{2,6} , Giuliano Tosello² , Fabricio Brenelli^{2,7,8} , Beatriz Geronymo^{2,9} , Daniel de Araujo Buttros^{2,10} , Bruna Salani Mota¹¹ , Henrique Lima Couto² , Benedito de Sousa Almeida Filho¹² , Gustavo Machado Badan¹³ , Augusto Tufi Hassan² 

ABSTRACT

Objective: To establish evidence-based clinical guidelines from the 2025 International Symposium on Breast Diseases of Inland São Paulo (SIMIP 2025), addressing four key axes of breast cancer diagnosis and management: indications for preoperative magnetic resonance imaging (MRI), vacuum-assisted excision (VAE) for B3 lesions (breast lesions of uncertain malignant potential), supplemental imaging for dense breasts, and the preferred imaging modality (contrast-enhanced mammography [CEM] or MRI) for high-risk women. **Methods:** Each axis was presented in evidence-based lectures, followed by debates and anonymous electronic voting by 100 specialists. Consensus was defined as $\geq 75\%$ agreement. **Results:** Preoperative MRI was recommended for selected cases (100% in favor), including invasive lobular carcinoma, dense breasts, and occult carcinoma. VAE for B3 lesions received 98% support, except for phyllodes tumors and papillary lesions with atypia. Supplemental imaging for dense breasts was unanimously endorsed (64% preferred MRI, 36% voted for ultrasound). For high-risk women, MRI was chosen by 100%, with CEM as an alternative. **Conclusion:** The guidelines reinforce MRI for selected preoperative cases and high-risk screening, emphasize VAE as an effective approach for managing B3 lesions, and advocate for supplemental imaging (preferably MRI) for dense breasts, with multidisciplinary decision-making.

KEYWORDS: breast cancer; magnetic resonance imaging; vacuum-assisted excision; B3 lesions; dense breasts; high risk screening.

INTRODUCTION

Breast cancer is the most common malignant neoplasm in women, requiring precise strategies for early detection and optimized management. Preoperative magnetic resonance imaging (MRI) is notable for its high sensitivity, but its routine use is debated due to false positives and high costs¹⁻⁸. B3 lesions, characterized by uncertain malignant potential, pose a clinical

challenge, with vacuum-assisted excision (VAE) emerging as a minimally invasive alternative to surgery⁹⁻¹⁴. Dense breasts, present in 40–50% of women, reduce mammography sensitivity and increase cancer risk, necessitating supplemental imaging¹⁵⁻¹⁸. For high-risk women (>20% lifetime risk), choosing between MRI and contrast-enhanced mammography (CEM) is critical for effective screening¹⁹⁻²⁵. The 2025 International Symposium on

¹Universidade Estadual Paulista “Júlio de Mesquita Filho”, Faculdade de Medicina de Botucatu – São Paulo (SP), Brazil.

²Brazilian Society of Mastology – São Paulo (SP), Brazil.

³Hospital Israelita Albert Einstein, Centro de Oncologia – São Paulo (SP), Brazil.

⁴Faculdade de Ciências Médicas da Santa Casa de São Paulo – São Paulo (SP), Brazil.

⁵Faculdade Israelita de Ciências da Saúde Albert Einstein – São Paulo (SP), Brazil.

⁶Universidade Federal de São Paulo, Undergraduate Course and Benign and High-Risk Breast Disease Clinic Coordinator at the Mastology Division – São Paulo (SP), Brazil.

⁷Universidade Estadual de Campinas, Breast Oncology Division – Campinas (SP), Brazil.

⁸São Paulo Society of Mastology – São Paulo (SP), Brazil.

⁹Hospital Beneficência Portuguesa – São Paulo (SP), Brazil.

¹⁰Universidade Estadual Paulista “Júlio de Mesquita Filho”, Graduate Program in Obstetrics and Gynecology – Botucatu (SP), Brazil.

¹¹Universidade de São Paulo, Faculdade de Medicina, Instituto Octávio Frias de Oliveira – São Paulo (SP), Brazil.

¹²Universidade Estadual Paulista “Júlio de Mesquita Filho”, Breast Assessment Center – São Paulo (SP), Brazil.

¹³Hospital Santa Catarina – São Paulo (SP), Brazil.

Corresponding author: ec.pessoa@unesp.br

Conflict of interests: nothing to declare. **Funding:** none.

Received on: 06/26/2025. **Accepted on:** 08/15/2025

Breast Diseases of Inland São Paulo, held in the city of Campinas, convened experts to define evidence-based guidelines for these four thematic domains, aiming to guide clinical practice in the Brazilian context.

METHODS

The symposium addressed four main topics: (1) indications for preoperative MRI; (2) use of VAE for managing B3 lesions; (3) supplemental imaging for screening dense breasts; and (4) choice between CEM and MRI for high-risk women.

Each topic was presented in a 10-minute lecture based on a literature review, followed by 50 minutes of expert debate. Voting was conducted electronically and anonymously, with participation of 100 professionals—mastologists, radiologists, and oncologists. Consensus was defined as $\geq 75\%$ agreement. Results were compiled into practical clinical guidelines tailored to the Brazilian public and private healthcare contexts.

RESULTS AND DISCUSSION

1. Indications for preoperative breast magnetic resonance imaging

Introduction to the topic

Preoperative MRI is a highly sensitive tool for assessing tumor extent, particularly in invasive lobular carcinoma (ILC), dense breasts, and occult carcinoma. However, its routine use is questioned due to false positives, unnecessary biopsies, and high costs.

Rationale and evidence

- **Sensitivity and specificity:** MRI has a sensitivity of 90–95% and specificity of 80–85%, but false positives lead to additional biopsies^{4,5}.
- **Clinical impact:** A meta-analysis by Mota et al., including five randomized controlled trials with 1,856 patients who underwent MRI and 2,014 who did not, showed no significant reduction in reoperations¹. However, the Magnetic Resonance Imaging in the Preoperative Assessment of Invasive Lobular Carcinoma (MIPA in ILC) study (2022) reported a reduction in reoperations from 12.8% (without MRI) to 1.9% (with MRI)⁶. Ha et al. corroborated lower reoperation rates in ILC².
- **Mastectomy:** Lobbes et al. observed reduced primary mastectomies and positive margins in ILC, but increased mastectomy rates in invasive ductal carcinoma³.
- **Breast density:** Sassi et al. reported higher detection rates of malignant lesions in dense breasts⁴. Onega et al. noted 11% additional biopsies with MRI, more frequent in dense breasts (27.4% vs. 16.2% in Category A of the Breast Imaging Reporting and Data System [Bi-Rads[®]])⁵.

- **Occult carcinoma:** In patients with axillary metastasis and an unidentified primary tumor by mammography or ultrasound (US), MRI is essential for locating the primary focus, guiding therapy, and potentially avoiding radical mastectomies²⁶.
- **Advantages:** MRI improves staging, detects multifocal/multicentric disease, and aids insurgical/oncoplastic planning^{1,7}.
- **Limitations:** MRI is associated with false positives (22.6% vs. 5.1% for other methods), additional biopsies, and gadolinium-related risks (e.g., allergy <1%, nephrogenic systemic fibrosis)^{1,5}.

Voting results

- Never order: 0%
- Selected cases: 100%
- Always order: 0%

Practical recommendations

- **Indications:**
 - Dense breasts (Category C/D)⁴.
 - ILC to reduce reoperations².
 - High familial risk without recent MRI¹.
 - Suspected extensive disease (multifocal/multicentric)⁷.
 - Occult carcinoma with axillary metastasis²⁶.
 - Surgical/oncoplastic planning¹.
- **Decision:** MRI should be individualized through a multidisciplinary discussion, avoiding routine use due to costs and false positives.

Conclusion

Preoperative MRI is recommended for selected cases but should not be used routinely.

2. Minimally invasive treatment (vacuum-assisted excision) for B3 lesions

Introduction to the topic

B3 lesions, present in 5–10% of breast biopsies, have a malignancy risk of 8–35% (mean 16–20%)⁹. VAE, distinct from vacuum-assisted biopsy (VAB), is a therapeutic procedure that completely removes lesions (<15 mm), reducing the need for surgery^{11,13}.

Rationale and evidence

- **VAB vs. VAE:** VAB is diagnostic, collecting fragments, while VAE is therapeutic, removing entire lesions (~ 4 g)^{11,13}.
- **Efficacy:** VAE avoids surgery in 78.3% of B3 lesions with atypia and 65.1% without atypia¹⁰. For lesions <15 mm, it achieves complete resection¹¹.
- **B3 subtypes:** Forester et al. indicated a higher malignancy risk in atypical ductal hyperplasia (ADH) and papillary lesions with atypia⁹.
- **Indications and exceptions:**

- VAE: Recommended for flat epithelial atypia, lobular neoplasia, papillary lesions without atypia, radial scars, and sclerosing lesions¹⁴.
- Phyllodes tumors: Contraindicated for VAE, except in small (<15 mm), low-proliferative lesions, after multidisciplinary discussion, due to recurrence risk^{12,14}.
- Papillary lesions with atypia: Generally require surgical excision, but VAE may be considered after multidisciplinary evaluation^{13,14}.
- ADH: Contraindicated in core needle biopsy, but VAE is feasible in VAB for small, unifocal lesions, after multidisciplinary discussion¹⁴.
- **Safety:** Couto reported hematomas in 54% of cases (Grade 1: 29%; Grade 2: 11%; Grade 3: 10%; Grade 4: 4%) and skin lacerations in 13%¹². McMahon et al. reported 68.5% of surgeries avoided and 66.7% of cancers treated in a single step¹¹.
- **Guidelines:** The 3rd International Consensus (2023) recommends VAE for B3 lesions in core needle biopsy, except ADH and phyllodes tumors. For VAB, VAE is sufficient with complete resection, followed by radiologic follow-up¹⁴.
- **Limitations:** VAE does not assess margins and is contraindicated for extensive lesions (>15 mm)¹³.

Voting results

- Yes: 98%
- No: 2%

Practical recommendations

- **Indications:** For flat epithelial atypia, lobular neoplasia, papillary lesions without atypia, radial scars, and sclerosing lesions (<15 mm)¹⁴.
- **Exceptions:**
 - Phyllodes tumors: VAE only for small, low-proliferative lesions, after multidisciplinary discussion¹⁴.
 - Papillary lesions with atypia: Prefer surgical excision¹⁴.
- **Monitoring:** Annual imaging (mammography, US, MRI) for four years. If malignancy is detected, surgery should be planned¹².
- **Advantages:** Avoids hospitalization, scarring, and is cost-effective¹⁰.
- **Decision:** Multidisciplinary, considering size, histology, and risk.

Conclusion

VAE is effective for managing most B3 lesions, except phyllodes tumors and papillary lesions with atypia, offering a safe, minimally invasive alternative.

3. Supplemental imaging for screening in dense breasts

Introduction to the topic

Dense breasts (Category C/D in Bi-Rads[®]) reduce mammography sensitivity (62–68%) and increase cancer risk by 4–6 times,

necessitating supplemental imaging. In Brazil, only 40% of women undergo screening, with >55% of diagnoses occurring at advanced stages¹⁵.

Rationale and evidence

- **Mammography:** Low sensitivity in dense breasts¹⁶.
- **US:** Sensitivity of 80–83%, detects 2–7 cancers/1,000, but has false positives¹⁷.
- **MRI:** Sensitivity of 90–95%, detects 16–20 cancers/1,000, reduces interval cancers by 84%¹⁸.
- **Cost-effectiveness:** MRI is feasible for high-risk patients, while US is more accessible¹⁵.

Voting results

- Yes, preferably US: 36%
- Yes, preferably MRI: 64%
- No: 0%

Practical recommendations for supplemental imaging in dense breasts:

- **Indications:**
 - MRI: Dense breasts (Category C/D) with high risk (BRCA1/2, Gail risk $\geq 20\%$), annual with mammography¹⁸.
 - US: Moderate risk when MRI is unavailable, annual with mammography¹⁷.
- **Strategy:**
 - High risk: MRI is the standard for screening, combined with mammography.
 - Moderate risk: Supplement mammography with MRI or US if MRI is unavailable.
 - Population risk: Discuss case-by-case benefits and drawbacks of supplemental methods (MRI /US) and personalize screening¹⁵.

Conclusion

Supplemental imaging, preferably MRI, is essential for dense breasts, with US as an accessible alternative, especially in resource-limited settings.

4. Preferred imaging for high-risk women: contrast-enhanced mammography or magnetic resonance imaging

Introduction to the topic

High-risk women (>20% lifetime risk) require intensive screening. MRI and CEM are viable options, but the ideal choice depends on sensitivity, specificity, cost, and access.

Rationale and evidence

- **MRI:** Sensitivity of 90–100%, specificity of 80–94%, detects early lesions without radiation²¹. The abbreviated protocol maintains

sensitivity (81.8–100%) and reduces costs²². Limitations include cost, false positives, and contraindications¹⁹.

- **CEM:** Sensitivity of 95–95.9%, specificity of 81–81.8%, lower cost (US\$196 vs. US\$775)²⁴. Detects 13.1/1,000 cancers but is less sensitive for early lesions²³.
- **Comparison:** A prospective study (2023) showed MRI (abbreviated protocol and full) superior in sensitivity, but CEM with higher specificity²⁵.

Voting results

- CEM: 0%
- MRI: 100%

Practical recommendations

- **Indications:**
 - MRI: Preferred for high risk (BRCA1/2, genetic syndromes), annual with mammography, preferably abbreviated protocol²¹.
 - CEM: Alternative if MRI is unavailable or contraindicated, for dense breasts or intermediate-high risk²³.
- **Strategy:**
 - High risk: MRI + mammography annually, starting at age 25–30.
 - Intermediate-high risk: MRI + mammography; CEM if MRI is infeasible.

Conclusion

MRI is the preferred imaging for high-risk women, with CEM as a viable alternative in settings with limited access or contraindications.

CONCLUSIONS

The 2025 International Symposium on Breast Diseases of Inland São Paulo guidelines reinforce the following recommendations:

- **Preoperative MRI:** Indicated for selected cases, such as ILC, dense breasts, occult carcinoma, and high risk, but not routinely due to costs and false positives^{1-6,26}.
- **VAE for B3 lesions:** Effective for managing most B3 lesions, except phyllodes tumors, papillary lesions with atypia, and ADH (except in selected cases), as a minimally invasive alternative⁹⁻¹⁴.
- **Dense breasts:** Supplemental imaging, preferably MRI, is essential, with US as an accessible alternative in resource-limited settings¹⁵⁻¹⁸.
- **High risk:** MRI is superior for screening, with CEM as a secondary option in restricted access or contraindicated cases¹⁹⁻²⁵.

ACKNOWLEDGMENTS

The authors would like to acknowledge the valuable contributions of the following individuals for their participation in discussions, support in technical analysis, or collaboration in organizing the

2025 International Symposium on Breast Diseases of Inland São Paulo: Adriana Akemi Yoshimura, Ailton Joioso, Alexandre Vicente de Andrade, Andre Mattar, Andrea Cavalheiro Horta Cubero, Angela Francisca Trinconi, Aricia Helena G. Giribela, Augusto Tufi Hassan, Benedito de Sousa Almeida Filho, Bruna Salani Mota, Carla Priscila Kamiya Carvalho Pessoa, Carlos Alberto da Silva Giandon, Carlos Alberto Ruiz, Carolina Nazareth Valadares, César Cabello dos Santos, Edison Mantovani Barbosa, Evandro Fallaci Mateus, Fabiana Baroni Alves Makdissi, Fabiana Coelho, Fabio Francisco Oliveira Rodrigues, Felipe Andreotta Cavagna, Felipe Pereira Zerwes, Fernanda Barbosa Coelho Rocha, Filomena Marino Carvalho, Francisco Pimentel Cavalcante, Franklin Fernandes Pimentel, Gil Facina, Giuliano Mendes Duarte, Guilherme Novita, Gustavo Machado Badan, Heloisa Maria de Luca Vespoli, Henrique Lima Couto, Idam de Oliveira Junior, Ivo Carelli Filho, Joao Bosco Ramos Borges, Joao Ricardo Auler Paloschi, Joaquim Teodoro de Araujo Neto, Jose Francisco Rinaldi, Jose Luis Esteves Francisco, José Ricardo Paciência Rodrigues, Jose Roberto Filassi, Jose Roberto Salina, Juliana Francisco, Lincon Jo Mori, Livia Conz, Luiz Antonio Guimaraes Brondi, Marcelo Antonini, Maria do Socorro Maciel, Mariana Burity Xavier, Nassif Galeb Junior, Natalie Rios Almeida, Odair Ferraro, Paulo Gustavo Tenorio do Amaral, Paulo Pirozzi, Rafaela Cecilio Sahium, Renata Arakelian, Renata Suzuki Brondi, Renato Cagnacci Neto, Renato Torresan, Ricardo Costa Pinto, Rogério Fenile, Rosemar Macedo Sousa Rahal, Silvio Eduardo Bromberg, Simone Elias, Thamyse Fernanda de Sa Dassie, Vicente Tarricone Junior, Vinicius Breda Pereira, Wellerson Miranda, Therezinha de Jesus Motta Figueira, Paulo Gil Katsuda, Rafael José Fábio Pelorca, Maria Beatriz de Paula Leite Kraft, Ana Baccarin, Gustavo Antonio de Souza, Anastasio Berrettini Junior, Daniel Luiz Gimenes, Leonardo Fleury Orlandini, Carlos Henrique dos Anjos, Pedro Moraes, Carlos Elias Fristachi, Sheila Wludarski, Silas Otero Reis Salum, Julio Cesar Narciso Gomes, Robson Ferrigno, Giovanna Azevedo Gabriele Carlos, Michael Alvarado, Luca Chini Rinaldi, Tais Chebat Watanabe, Nathalia Oliveira Lemos, Marina Sconzo Polydoro, Carolina Estermeire Lima Carneiro, Talita Aparecida Mendes Riegas, Bruno Carvalho Carelli, and Marcelo Cruz.

AUTHORS' CONTRIBUTION

ECP: Conceptualization, Methodology, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. FB: Investigation, Methodology, Validation, Writing – review & editing. MM: Investigation, Methodology, Writing – review & editing, Validation. JTAN: Data curation, Investigation, Validation, Writing – review & editing. GT: Investigation, Validation, Writing – review & editing. FB: Investigation, Methodology, Validation, Writing – review & editing. BG: Data curation, Investigation, Writing – review & editing. DAB: Methodology, Validation, Writing – review & editing.

BSM: Formal Analysis, Investigation, Validation, Writing – review & editing. HLC: Investigation, Methodology, Validation, Writing – review & editing. BSAF: Data curation, Investigation, Writing

– review & editing. GMB: Investigation, Methodology, Validation, Writing – review & editing. ATH: Supervision, Validation, Writing – review & editing.

REFERENCES

- Mattar A, Antonini M, Amorim A, Mateus EF, Bagnoli F, Cavalcante FP, et al. PROMRIINE (PRE-operative Magnetic Resonance Imaging is INEffective) Study: A Systematic Review and Meta-analysis of the Impact of Magnetic Resonance Imaging on Surgical Decisions and Clinical Outcomes in Women with Breast Cancer. *Ann Surg Oncol*. 2024;31(12):8021-9. <https://doi.org/10.1245/s10434-024-15833-5>
- Ha SM, Chae EY, Cha JH, Kim HH, Shin HJ, Choi WJ. Breast MR Imaging before Surgery: Outcomes in Patients with Invasive Lobular Carcinoma by Using Propensity Score Matching. *Radiology*. 2018;287(3):771-7. <https://doi.org/10.1148/radiol.2018171472>
- Lobbjes MBI, Vriens IJH, van Bommel ACM, Nieuwenhuijzen GAP, Smidt ML, Boersma LJ, et al. Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers. *Breast Cancer Res Treat*. 2017;162(2):353-64. <https://doi.org/10.1007/s10549-017-4117-8>
- Sassi A, Salminen A, Jukkola A, Tervo M, Mäenpää N, Turtiainen S, et al. Breast density and the likelihood of malignant MRI-detected lesions in women diagnosed with breast cancer. *Eur Radiol*. 2023;33(11):8080-8. <https://doi.org/10.1007/s00330-023-10072-w>
- Onega T, Zhu W, Kerlikowske K, Miglioretti DL, Lee CI, Henderson LM, et al. Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield. *Breast Cancer Res Treat*. 2022;191(1):177-90. <https://doi.org/10.1007/s10549-021-06418-x>
- Cozzi A, Di Leo G, Houssami N, Gilbert FJ, Helbich TH, Benito MÁ, et al. Preoperative breast MRI reduces reoperations for unilateral invasive lobular carcinoma: a patient-matched analysis from the MIPA study. *Eur Radiol*. 2025;35(7):3990-4000. <https://doi.org/10.1007/s00330-024-11338-7>
- Gonzalez V, Arver B, Löfgren L, Bergkvist L, Sandelin K, Eriksson S. Impact of preoperative breast MRI on 10-year survival of patients included in the Swedish randomized multicentre POMB trial. *BJS Open*. 2021;5(5):zrab088. <https://doi.org/10.1093/bjsopen/zrab088>
- Gonzalez V, Sandelin K, Karlsson A, Åberg W, Löfgren L, Iliescu G, et al. Preoperative MRI of the breast (POMB) influences primary treatment in breast cancer: a prospective, randomized, multicenter study. *World J Surg*. 2014;38(7):1685-93. <https://doi.org/10.1007/s00268-014-2605-0>
- Forester ND, Lowes S, Mitchell E, Twiddy M. High risk (B3) breast lesions: What is the incidence of malignancy for individual lesion subtypes? A systematic review and meta-analysis. *Eur J Surg Oncol*. 2019;45(4):519-27. <https://doi.org/10.1016/j.ejso.2018.12.008>
- Sharma N, Cornford E, Cheung S, Price H, Kearins O. The impact of vacuum-assisted excision in the management of indeterminate B3 lesions in the NHS Breast Screening Programme in England. *Clin Radiol*. 2021;76(6):470.e23-470.e29. <https://doi.org/10.1016/j.crad.2021.01.021>
- McMahon MA, Haigh I, Chen Y, Millican-Slater RA, Sharma N. Role of vacuum assisted excision in minimising overtreatment of ductal atypias. *Eur J Radiol*. 2020;131:109258. <https://doi.org/10.1016/j.ejrad.2020.109258>
- Couto HL. Preliminary unpublished data, 118 cases. Presented at EUSOBI Meeting Lisbon, October 5, 2024.
- Stergios K, Patel A, Pergialiotis V. Management of B3 lesions of the breast: implementations of current recommendations in clinical practice. *J BUON*. 2017;22(6):1587-90.
- Elfgen C, Leo C, Kubik-Huch RA, Muenst S, Schmidt N, Quinn C, et al. Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). *Virchows Arch*. 2023;483(1):5-20. <https://doi.org/10.1007/s00428-023-03566-x>
- Rosa DD, Bines J, Werutsky G, Barrios CH, Cronemberger E, Queiroz GS, et al. The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115). *Breast Cancer Res Treat*. 2020;183(3):749-57. <https://doi.org/10.1007/s10549-020-05831-y>
- Miglioretti DL, Zhu W, Kerlikowske K, Sprague BL, Onega T, Buist DSM, et al. Breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status. *JAMA Oncol*. 2015;1(8):1069-77. <https://doi.org/10.1001/jamaoncol.2015.3084>
- Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. *JAMA*. 2012;307(13):1394-404. <https://doi.org/10.1001/jama.2012.388>
- Kuhl CK, Strobel K, Bieling H, Leutner C, Schild HH, Schrading S. Supplemental breast MR imaging screening of women with average risk of breast cancer. *Radiology*. 2017;283(2):361-70. <https://doi.org/10.1148/radiol.2016161444>
- Monticciolo DL, Newell MS, Moy L, Lee CS, Destounis SV. Breast cancer screening for women at higher-than-average risk: Updated recommendations from the ACR. *J Am Coll Radiol*. 2023;20(9):902-14. <https://doi.org/10.1016/j.jacr.2023.04.002>
- Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers RD, Bieling HB. Abbreviated breast magnetic resonance imaging (MRI): First postcontrast subtracted images and maximum-intensity projection — a novel approach to breast cancer screening with MRI. *J Clin Oncol*. 2014;32(22):2304-10. <https://doi.org/10.1200/JCO.2013.52.5386>

21. Milon A, Wahab CA, Kermarrec E, Bekhouche A, Taourel P, Thomassin-Naggara I. Breast MRI: Is faster better? *AJR Am J Roentgenol.* 2020;214(2):282-95. <https://doi.org/10.2214/AJR.19.21924>.
22. Sorin V, Rahman N, Halabi N, Barash Y, Klang E, Sklair-Levy M. Evaluating ten years of breast cancer screening with contrast-enhanced mammography in women with intermediate-high risk. *Eur J Radiol.* 2024;181:111807. <https://doi.org/10.1016/j.ejrad.2024.111807>
23. Cozzi A, Magni V, Zanardo M, Schiaffino S, Sardanelli F. Contrast-enhanced mammography: A systematic review and meta-analysis of diagnostic performance. *Radiology.* 2022;302(3):568-81. <https://doi.org/10.1148/radiol.211412>
24. Coffey K, Jochelson MS. Contrast-enhanced mammography in breast cancer screening. *Eur J Radiol.* 2022;156:110513. <https://doi.org/10.1016/j.ejrad.2022.110513>
25. Lawson MB, Partridge SC, Hippe DS, Rahbar H, Lam DL, Lee CI, et al. Comparative performance of contrast-enhanced mammography, abbreviated breast MRI, and standard breast MRI for breast cancer screening. *Radiology.* 2023;308(2):e230576. <https://doi.org/10.1148/radiol.230576>
26. Mann RM, Kuhl CK, Kinkel K, Boetes C. Breast MRI: guidelines from the European Society of Breast Imaging. *Eur Radiol.* 2008;18(7):1307-18. <https://doi.org/10.1007/s00330-008-0863-7>

